Company intelligence / Profile preview
ActivX Biosciences, Inc.
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
Overview
ActivX Biosciences developed small molecule drugs targeting protein kinases and proteases. The company was acquired in 2005 by Kyorin Pharmaceutical Co. Ltd. Their KiNativ platform provides quantitative profiling of kinase inhibitors against native kinases in cell or tissue lysates.
- Therapeutic areas
- HematologyImmunologyOncologyMetabolic Disorders
- Modalities
- Small molecule drugs
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on ActivX Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActivX Biosciences, Inc..